These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 16337231

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Structural and thermodynamic study on aldose reductase: nitro-substituted inhibitors with strong enthalpic binding contribution.
    Steuber H, Heine A, Klebe G.
    J Mol Biol; 2007 May 04; 368(3):618-38. PubMed ID: 17368668
    [Abstract] [Full Text] [Related]

  • 3. Probing flexibility and "induced-fit" phenomena in aldose reductase by comparative crystal structure analysis and molecular dynamics simulations.
    Sotriffer CA, Krämer O, Klebe G.
    Proteins; 2004 Jul 01; 56(1):52-66. PubMed ID: 15162486
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Tracing changes in protonation: a prerequisite to factorize thermodynamic data of inhibitor binding to aldose reductase.
    Steuber H, Czodrowski P, Sotriffer CA, Klebe G.
    J Mol Biol; 2007 Nov 09; 373(5):1305-20. PubMed ID: 17905306
    [Abstract] [Full Text] [Related]

  • 6. Structure of human aldose reductase holoenzyme in complex with statil: an approach to structure-based inhibitor design of the enzyme.
    El-Kabbani O, Ramsland P, Darmanin C, Chung RP, Podjarny A.
    Proteins; 2003 Feb 01; 50(2):230-8. PubMed ID: 12486717
    [Abstract] [Full Text] [Related]

  • 7. Expect the unexpected or caveat for drug designers: multiple structure determinations using aldose reductase crystals treated under varying soaking and co-crystallisation conditions.
    Steuber H, Zentgraf M, Gerlach C, Sotriffer CA, Heine A, Klebe G.
    J Mol Biol; 2006 Oct 13; 363(1):174-87. PubMed ID: 16952371
    [Abstract] [Full Text] [Related]

  • 8. Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors.
    El-Kabbani O, Darmanin C, Schneider TR, Hazemann I, Ruiz F, Oka M, Joachimiak A, Schulze-Briese C, Tomizaki T, Mitschler A, Podjarny A.
    Proteins; 2004 Jun 01; 55(4):805-13. PubMed ID: 15146479
    [Abstract] [Full Text] [Related]

  • 9. The alrestatin double-decker: binding of two inhibitor molecules to human aldose reductase reveals a new specificity determinant.
    Harrison DH, Bohren KM, Petsko GA, Ringe D, Gabbay KH.
    Biochemistry; 1997 Dec 23; 36(51):16134-40. PubMed ID: 9405046
    [Abstract] [Full Text] [Related]

  • 10. Merging the binding sites of aldose and aldehyde reductase for detection of inhibitor selectivity-determining features.
    Steuber H, Heine A, Podjarny A, Klebe G.
    J Mol Biol; 2008 Jun 20; 379(5):991-1016. PubMed ID: 18495158
    [Abstract] [Full Text] [Related]

  • 11. The crystallographic structure of the aldose reductase-IDD552 complex shows direct proton donation from tyrosine 48.
    Ruiz F, Hazemann I, Mitschler A, Joachimiak A, Schneider T, Karplus M, Podjarny A.
    Acta Crystallogr D Biol Crystallogr; 2004 Aug 20; 60(Pt 8):1347-54. PubMed ID: 15272156
    [Abstract] [Full Text] [Related]

  • 12. Aldose and aldehyde reductases: structure-function studies on the coenzyme and inhibitor-binding sites.
    El-Kabbani O, Old SE, Ginell SL, Carper DA.
    Mol Vis; 1999 Sep 03; 5():20. PubMed ID: 10493777
    [Abstract] [Full Text] [Related]

  • 13. Ultrahigh resolution drug design I: details of interactions in human aldose reductase-inhibitor complex at 0.66 A.
    Howard EI, Sanishvili R, Cachau RE, Mitschler A, Chevrier B, Barth P, Lamour V, Van Zandt M, Sibley E, Bon C, Moras D, Schneider TR, Joachimiak A, Podjarny A.
    Proteins; 2004 Jun 01; 55(4):792-804. PubMed ID: 15146478
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Crystal structure of calf spleen purine nucleoside phosphorylase with two full trimers in the asymmetric unit: important implications for the mechanism of catalysis.
    Bzowska A, Koellner G, Wielgus-Kutrowska B, Stroh A, Raszewski G, Holý A, Steiner T, Frank J.
    J Mol Biol; 2004 Sep 17; 342(3):1015-32. PubMed ID: 15342253
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Kinetic and spectroscopic evidence for active site inhibition of human aldose reductase.
    Nakano T, Petrash JM.
    Biochemistry; 1996 Aug 27; 35(34):11196-202. PubMed ID: 8780524
    [Abstract] [Full Text] [Related]

  • 19. High-resolution structures of human aldose reductase holoenzyme in complex with stereoisomers of the potent inhibitor Fidarestat: stereospecific interaction between the enzyme and a cyclic imide type inhibitor.
    El-Kabbani O, Darmanin C, Oka M, Schulze-Briese C, Tomizaki T, Hazemann I, Mitschler A, Podjarny A.
    J Med Chem; 2004 Aug 26; 47(18):4530-7. PubMed ID: 15317464
    [Abstract] [Full Text] [Related]

  • 20. Probing the ultra-high resolution structure of aldose reductase with molecular modelling and noncovalent mass spectrometry.
    Darmanin C, Chevreux G, Potier N, Van Dorsselaer A, Hazemann I, Podjarny A, El-Kabbani O.
    Bioorg Med Chem; 2004 Jul 15; 12(14):3797-806. PubMed ID: 15210146
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.